Physician Library

Educational materials to help you and your staff talk to patients about BPH and the UroLift® System.

Source Information

  1. Roehrborn et al. Can J Urol 2017
  2. AUA Guidelines 2003, 2020
  3. Wasson, Perspectives in Nursing 2000
  4. NIH U.S. National Library of Medicine – TURP patient instructions https://medlineplus.gov/ency/patientinstructions/000300.htm
  5. Sonksen, EU Urol, 2015 BPH6 Study
  6. Berry et al, J Urol 1984
  7. Roehrborn, J Urol 2013
  8. Mirakhur, Can Assoc Rad J 2017
  9. McVary, J Urol 2016
  10. Gilling, Can J Urol 2020
  11. Kadner, World J Urol 2020

 *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T pivotal

INFORMATION FOR PATIENTS ABOUT THE UROLIFT® SYSTEM

The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), available for men 50 years or older with an enlarged prostate up to 100 cc who are looking for an alternative to drugs or major surgeries.
 

The UroLift System’s implants, which can be delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue.

The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.1 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*2-4

Most common side effects are temporary and can include pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate and/or the inability to control the urge.5 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention.

Treatment using the UroLift System is not appropriate if you have a prostate volume greater than 100cc, a urinary tract infection or other conditions that can be identified by your urologist.

Individual results with the UroLift System may vary.

WARNINGS:
1) THE UROLIFT SYSTEM’S IMPLANTS ARE PERMANENT (THAT IS TO SAY: ONCE IMPLANTED, THEY CANNOT BE COMPLETELY REMOVED).

2) THE UROLIFT SYSTEM’S IMPLANTS CONTAIN STAINLESS STEEL AND NITINOL, AN ALLOY OF NICKEL AND TITANIUM. INDIVIDUALS WHO ARE ALLERGIC TO THESE METALS MAY SUFFER AN ALLERGIC REACTION TO THE IMPLANT. PRIOR TO HAVING A UROLIFT SYSTEM PROCEDURE, YOU SHOULD DISCUSS ANY ALLERGY/HYPERSENSITIVITY TO THESE MATERIALS WITH YOUR UROLOGIST.

3) THE ABOVEMENTIONED INFORMATION IS NOT INTENDED TO PROVIDE MEDICAL ADVICE TO PATIENTS OR TO REPLACE THEIR DOCTORS' EXPERT OPINION AND CARE.

4) ONLY A DOCTOR CAN DIAGNOSE WHETHER HIS/HER PATIENT HAS BPH, ASSESS HIS INDIVIDUAL CONDITION AND DEFINE WHETHER UROLIFT SYSTEM IS THE ADEQUATE TREATMENT OR NOT.

5) TALK TO YOUR UROLOGIST FOR MORE INFORMATION ABOUT THE UROLIFT SYSTEM AND TO DETERMINE IF IT IS THE RIGHT TREATMENT FOR YOU.

*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.

  1. Rukstalis, Prostate Cancer and Prostatic Dis 2018
  2. Roehrborn, Can J Urol 2017
  3. AUA BPH Guidelines 2003, 2020
  4. McVary, J Sex Med 2016
  5. Roehrborn, J Urology 2013

INFORMATION FOR PHYSICIANS ABOUT THE UROLIFT® SYSTEM

The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years or older. The UroLift implants are permanent and can be delivered during an outpatient procedure, relieving prostate obstruction without heating, cutting, destructing, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.1 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*2-4 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.5 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines.
 
Contraindicated in men with a prostate volume greater than 100cc or a urinary tract infection.
 
Warning: This device contains stainless steel and nitinol, an alloy of nickel and titanium. Persons with allergic reactions to these metals may suffer an allergic reaction to this implant. Prior to implantation, patients should be counseled on the materials contained in the device, as well as potential for allergy/hypersensitivity to these materials.

Individual results may vary. For full information, please consult the Instructions for Use (IFU)

*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.

  1. Rukstalis, Prostate Cancer and Prostatic Dis 2018
  2. Roehrborn, Can J Urol 2017
  3. AUA BPH Guidelines 2003, 2020
  4. McVary, J Sex Med 2016
  5. Roehrborn, J Urology 2013

 

Teleflex, BPH Relief In Sight and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. ©2023 Teleflex Incorporated. All rights reserved. Revised: 02/2023. MC-008657 LA EN

Teleflex Medical Brasil Ltda
Rua Alexandre Dumas, 2100/132 - Chacara Santo Antonio
São Paulo/SP - CEP 04717-913